Practical applications of a new botulinum toxin.
The injection of Clostridium botulinum type A neurotoxins is among the most commonly performed cosmetic procedures, both in the U.S. and worldwide. The U.S. Food and Drug Administration (FDA) approval of a new botulinum neurotoxin type A in April 2009 (BoNT-A, Dysport, Medicis, Scottsdale, AZ-hereafter referred to as "Dysport") has broadened the neurotoxin market and provides new therapeutic alternatives to practitioners. The introduction of this product raises questions about how to best use it. In this supplement, the authors address critical similarities and differences between onabotulinumtoxinA (Botox, Allergan, Irvine, CA--hereafter referred to as "Botox") and abobotulinumtoxinA (Dysport). The authors also provide practical guidelines for the use of Dysport based on clinical experience and peer-reviewed, published clinical trials. In the authors' opinion, Botox and Dysport can be used for similar "on-" and "off-label" applications. Judicious use of either product requires an understanding of how the two products differ in order to avoid side effects and achieve optimal results. Common Questions: Are these two toxins the same or different and how? How are inter-product "unit" conversions addressed? Does injection technique differ? Does one product result in greater adverse events? Does one product last longer or "diffuse" better than the other? What other toxins can be expected on the market in the future?
Hexsel
Doris
D
Department of Dermatology at the Pontificia Universidade Catolica do Rio Grande do Sul, Brazil. dohexsel@terra.com.br
Spencer
James M
JM
Woolery-Lloyd
Heather
H
Gilbert
Erin
E
D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003357:Cosmetic Techniques; D017277:Drug Approval; D006801:Humans; D009465:Neuromuscular Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D009498:Neurotoxins / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D056687:Off-Label Use; D017410:Practice Guidelines as Topic; D014481:United States; D014486:United States Food and Drug Administration
D009465:Neuromuscular Agents; D009498:Neurotoxins; D019274:Botulinum Toxins, Type A